http://www.pharmaasia.comPharmaAsia - Drug Deliveryen-USCopyright 2012 Ten Alps Communications Asia. All rights reserved.Thu, 9 Feb 2012 19:12:23 +0800http://www.pharmaasia.com/article/novozymes-biopharma-wins-technology-innovation-award/9323Novozymes Biopharma has received the 2012 Drug Delivery Partnerships (DDP) Technology Innovation award for the company’s half-life extension platform. The award recognizes the most exciting delivery technology of the year.http://www.pharmaasia.com/article/novozymes-biopharma-wins-technology-innovation-award/9323Wed, 8 Feb 2012 00:00:00 +0800http://www.pharmaasia.com/article/bio-images-and-medimetrics-partner-to-deliver-the-next-generation-of-smart-pill-technology/9261IntelliCap set to speed up clinical research as part of innovative drug delivery package.http://www.pharmaasia.com/article/bio-images-and-medimetrics-partner-to-deliver-the-next-generation-of-smart-pill-technology/9261Tue, 25 Oct 2011 00:00:00 +0800http://www.pharmaasia.com/article/bio-images-group-expands-its-presence-in-asia-pacific/9237To exhibit at AusBiotech 2011 in Adelaide, South Australia this October.http://www.pharmaasia.com/article/bio-images-group-expands-its-presence-in-asia-pacific/9237Mon, 10 Oct 2011 00:00:00 +0800http://www.pharmaasia.com/article/agilent-technologies-and-chungnam-national-university-collaborate-to-further-glycomics-research/9190Agilent Technologies Inc and Chungnam National University announced an agreement to develop new applications, methods, technologies and software tools in the field of glycomics, the study of complex sugars. The university aims to identify and deve…http://www.pharmaasia.com/article/agilent-technologies-and-chungnam-national-university-collaborate-to-further-glycomics-research/9190Tue, 23 Aug 2011 00:00:00 +0800http://www.pharmaasia.com/article/lipocine-chairman-awarded-order-of-the-rising-sun-by-japanese-government/9105Lipocine announces that Dr William Higuchi, Lipocine co-founder and Chairman of the Board, was awarded the ‘Order of The Rising Sun’ by the Japanese Government for “contribution to the development of Japanese pharmaceutics and pharmaceutical ch…http://www.pharmaasia.com/article/lipocine-chairman-awarded-order-of-the-rising-sun-by-japanese-government/9105Thu, 7 Jul 2011 00:00:00 +0800http://www.pharmaasia.com/article/pharmigene-secures-patents-to-warfarin-dosage-predictor/9058Pharmigene announced it has been granted patents in Europe, Japan, New Zealand, Mexico, Singapore, and Taiwan. The patents are related to methods used to predict dosage of the widely-prescribed anti-coagulant drug warfarin based on genetic variations…http://www.pharmaasia.com/article/pharmigene-secures-patents-to-warfarin-dosage-predictor/9058Fri, 3 Jun 2011 00:00:00 +0800http://www.pharmaasia.com/article/sanofi-aventis-signs-new-agreement-with-who-to-fight-neglected-tropical-diseases/8893Further $ 25 million donation raises prospects of eliminating sleeping sicknesshttp://www.pharmaasia.com/article/sanofi-aventis-signs-new-agreement-with-who-to-fight-neglected-tropical-diseases/8893Wed, 9 Mar 2011 00:00:00 +0800http://www.pharmaasia.com/article/rare-anti-influenza-antibodies/8470Scientists have identified a new, highly conserved molecular target on the influenza A virus and demonstrated that human antibodies against this target are protective in animal models of seasonal and highly-pathogenic avian influenza. The work wa…http://www.pharmaasia.com/article/rare-anti-influenza-antibodies/8470Thu, 1 Jul 2010 00:00:00 +0800http://www.pharmaasia.com/article/novartis-receives-approval-for-organ-rejection-prevention-drug/8427The US Food and Drug Administration (FDA) has approved Zortress (everolimus) oral tablets for the prevention of organ rejection of kidney transplants in adult patients at low-to-moderate immunologic risk. The drug is to be given in combination with r…http://www.pharmaasia.com/article/novartis-receives-approval-for-organ-rejection-prevention-drug/8427Thu, 27 May 2010 00:00:00 +0800http://www.pharmaasia.com/article/roche-and-osi-pharmaceuticals-gain-approval-for-cancer-treatment/8414Roche and OSI Pharmaceuticals have gained US Food and Drug Administration (FDA) approval for the use of Tarceva as a maintenance treatment for non-small cell lung cancer. The FDA's decision comes despite an earlier negative opinion from its advis…http://www.pharmaasia.com/article/roche-and-osi-pharmaceuticals-gain-approval-for-cancer-treatment/8414Wed, 26 May 2010 00:00:00 +0800